Tamoxifen (and SERMS)



Annie Appleseed Project newsletter SIGN UP

* required

*



Email Newsletter by VerticalResponse


Articles on Tamoxifen and Raloxifene can be found here.

March 2010: Recent studies have suggested that concomitant use of tamoxifen and CPY2D6 inhibitors, particularly paroxetine (Paxil), fluoxetine (Prozac), and bupropion (Wellbutrin), may worsen outcomes in breast cancer patients, including an increased mortality risk. Reported by www.medpagetoday.com from the European Breast Cancer Conference in Barcelona, Spain.

February 2010: Combining tamoxifen, the world’s most prescribed breast cancer agent, with a compound found in the flowering plant feverfew may prevent initial or future resistance to the drug, say researchers at Georgetown Lombardi Comprehensive Cancer Center.*************



Ann Fonfa testified at the 9/2/98 FDA Oncological Advisory committee when approval was granted for Tamoxifen use by healthy women.

Along with other activists who spoke passionately about their fears, confusion and general disillusionment with the drug, Ann remains very unhappy about the way the results of this study were reported on and promoted.

Please look at these articles, each of which stands alone as written at various times.

June 2009 American Society for Clinical Oncology annual meeting presentation found that certain popular antidepressants frequently prescribed to women taking the breast cancer drug tamoxifen more than double the risk of a breast cancer recurrence for those using both medications.

The antidepressants at issue are three widely used selective serotonin reuptake inhibitors (SSRIs), Prozac (fluoxetine), Paxil (paroxetine) and Zoloft (sertraline), and are among a group of drugs known as CYP2D6 inhibitors.

See below for more information from the press release.


Random Thoughts on the PREVENTION trials

Tamoxifen and Raloxifene 8/99

Canadian Analysis Finds No Improved Survival
Raloxifene:Benefits versus Risks
Benefit Greatest to Prevent Hormone-Dependent Bca
SPORE Study: New Guidelines for Tamoxifen Use

NCI Bulletin, 12/06

Low Dose Tamoxifen Effective: 1/20th?

Am Assoc for Cancer Research, 4/03

Press Release: Tam Effective at Lower Doses
2 Years Vs. 5 Years for Early Bca Age 50+
Excerpts:7th Intl Conf Adj Therapy

February 2001, Switzerland Includes basic info on the BCPT1

Drug Costs

A Comparison of Prices with some LINKS to Canadian pharmacies

BCPT1:Tamoxifen hearings 1998

Perspective and summary from Sharon Batt, a Canadian activist

Ann Fonfa's Testimony to the FDA 9/2/98
Washington Post Coverage, 9/98
Gail Model May Fail Women Under 40.

Journal, The Breast February 2001

Canada: Net Health Impact of Tamoxifen
Safe for Fewer Healthy Women

November 3, 1999 JNCI article

Study: Tamoxifen & Uterine Tumors
Tamoxifen Eligibility:PREVENTION in White Women
Tamoxifen Useful for Women 40-50 with 3.4% Five-Year Risk
Europe: Benefits/Risk of Tamoxifen-Healthy Women

Federation of European Cancer Societies 3/02

Tamoxifen and ER- Tumors

Another study demonstrates NOT helpful in Stage 1 ER-.

Era Of Hope Speech

Helen Schiff's passionate presentation on Tamoxifen for healthy women, 6/00

Questions and Answers on Tamoxifen
Press Release: Cancer Prevention Coalition

Barbara Seaman and Ann Fonfa also sign on to release

Letter: Wall Street Journal 1998

Written by Carol Hochberg and Ann Fonfa

IUD May Protect Tam Users

Study, The Lancet 11/00

STAR Trial

An article by Andrea Martin, Exec. Dir. The Breast Cancer Fund

Effect of Raloxifene on Bca Cell Ki67 and Apoptosis
Tam, Raloxifene Show Preclinical Cross-resistance
Tamoxifen & Beneficial Interactions

Cancer Letter 2000. early study results

Tamoxifen for Five Years
GLA and Tamoxifen May Down-Regulate ER Pathway
Black Cohosh & No Proliferation of Bca Cells
Tamoxifen Plus Soy Prevents Bca in Rats
Melatonin & Tamoxifen Good Combo
IP6 Enhances Adriamycin & Tamoxifen (Bca)
EPA Restores Tamoxifen Sensitivity (Akt activity)
Flaxseed Enhances Inhibitory Effect of Tamoxifen: ER+ Bca
Feverfew May Reduce Resistance to Tamoxifen
Symptoms & Adverse Effects: Reporting

Journal-The Breast, April 2001

Adverse Effects Not Properly Recorded
Tamoxifen & Depression
Toxicity of Antiestrogens
Tamoxifen Controversy-Negative Effects
Verbal Memory Impaired with Hormonal Therapy
Changes in Serum Triglycerides w/Tam
Gallstones Linked to Tamoxifen Use: Postmenopausal
Coagulation Behavior With Adj Post-op Tamoxifen
C-erb B2 Decreases Benefit of Adj Tam
Venous Thrombosis BCa Tamox/Chemo: Review
Tamoxifen w/Radiotherapy: CAUTION for Radiosensitive Pts
Tamoxifen for High Risk and BRCA1/2

Lancet, December 2000

Most Women with Family Hist DO NOT Get Bca
Tamoxifen and BRCA Mutations
Estimates of Prophylactic Effects of Tamoxifen *BRCA1&2)
Breast Cancer Prevention-UK Study
Breast Gel Version of Tamoxifen
Tamoxifen/Chemoprevent/BRCA1/2:Docs Recommendations
Chemoprevention Guidelines From Canada

Canadian Medical Association Journal, June 2001

Britain's Dept of Health Says No to Tamoxifen in Healthy Women
Tamoxifen and Risk of Contralateral Bca

JNCI,7/01

Author Musa Mayer Remarks on this Study
AP's Take:ER negative tumors develop After Tam Use
DNA Methylation Prfle Predicts Recurrence Risk:Tam/BCa
Benefits/Risk Tamoxifen Similar White & Black Women
Tamoxifen and Breast Tumor Vascularity

Breast Cancer Res Treat, 2001

Tam & Serum Leptin in Bca Pts

Jpn J of Clinical Oncology, 12/01

Tamoxifen's Effectiveness & Slow version of a Gene
FDA Warns AstraZeneca Over Ads

1/16/02 Reuters and FDA Website

Estrogen Level = Effect of Raloxifene

JAMA, 1/02

Cross-Resistance Tam Vs. Ralox
UK: Healthy Women,No Clear Benefit

The Oncologist, 2/02

Risk/Benefit in Int'l Intervention Study
Update on Royal Marsden Tamoxifen Prevention Trial
Aromatase Inhibitors/Estrogen Dominance

Peter D'Adamo, ND perspective, 2001

Use of Adjv Chemo in ATAC Trial-Nationality Correlates
Comparison of SERMS & Tamoxifen (MICE)

Intl J Cancer, 4/02

Age/Body Mass Affects Dose
FDA Presents: Tamoxifen & Uterine Sarcoma

Cancer Information Service Reports on ASCO 2002 presentation

Uterine Sarcoma Risk
Advocate Letter to FDA on Warning Labels, 2002
Risk Maliganant Mixed Mullerian Tumors *(Uterine)
HEALTHY PREVENTION

Some advice, information, and tips But mostly you must make your own informed decision

Recommendations: US Prev Svcs Task Force

Annals of Internal Medicine, 7/02 VERY IMPORTANT INFORMATION

Test  Developed: Who Needs Tamoxifen

Oncogene, 7/02

Age/Body Mass Index Affect Tam Metabolism

Presented at Dept of Defense Breast Cancer Res Conference, 9/02

Tamoxifen &  Benign Breast Disease

JNCI, 2/03

AIB1, Tam, Survival Issues

Press Release, JNCI 3/03

Acupuncture for Meno-symptoms w/Tamoxifen Use

Tumori, 3-4/02

Tamoxifen for Women with Breast Ca:Basics

Univ of Maryland, 5/03

Antidepressants supress Tamoxifen's Value

JNCI, 12/03

Raloxifene & Pre-menopausal Women

#A193 Frontiers in Cancer Prevention Res, 2003

Endocrine Therapy Better Than Chemo? ER+

SABCS, 12/03

Tamoxifen has Little Impact on Mortality
Antidepressants and Tamoxifen: Some Harmful

ASCO May/June 2009 presentation


Remember we are NOT Doctors and have NO medical training.

This site is like an Encyclopedia - there are many pages, many links on many topics.

Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.